Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

2.1K
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
2.1K
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

198
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
198
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

135
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
135
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

165
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
165
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

170
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
170

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repurposing Candidate Drugs to Prevent SARS-CoV-2: A PharmLines Test-Negative Case-Control Study.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Implementation of a deprescribing guideline by community pharmacists: A focus group study.

Exploratory research in clinical and social pharmacy·2026
Same author

Factors associated with medication adherence among people with type 2 diabetes in Indonesia: A multicenter cross-sectional study using structural equation modeling.

Journal of psychosomatic research·2026
Same author

To include or not to include? A prescription from the pharmacy on how to use active learning-assisted screening in systematic reviews.

Systematic reviews·2026
Same author

A Cross-Sectional Survey of Evidence Needs for Medicinal Products in Europe With a Focus on Real-World Evidence.

Pharmacoepidemiology and drug safety·2026
Same author

A Five-Year Study on Treatment Changes in Hypoglycemia-Associated Medications: Towards Personalized Diabetes Management.

Journal of personalized medicine·2026
Same journal

Safety of swallowed corticosteroids and their influence on the hypothalamic-pituitary-adrenal gland axis and on markers of bone resorption and formation in patients with eosinophilic esophagitis.

British journal of clinical pharmacology·2026
Same journal

A regulatory perspective on the first approved EU application to reformulate an inhaled medicine with a gas propellant with reduced global warming potential.

British journal of clinical pharmacology·2026
Same journal

Application of physiologically-based pharmacokinetic modelling to guide oral ketamine prescription in analgesic doses.

British journal of clinical pharmacology·2026
Same journal

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild-to-moderate asthma.

British journal of clinical pharmacology·2026
Same journal

Standardization of measurement and reporting of medication adherence using the TEN-SPIDERS tool for claims data.

British journal of clinical pharmacology·2026
Same journal

Anticholinergic and central nervous system-active drug burdens and their associations with adverse in-hospital outcomes among older inpatients.

British journal of clinical pharmacology·2026
See all related articles

Related Experiment Video

Updated: Apr 20, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.3K

Understanding drug preferences, different perspectives.

Peter G M Mol1,2, Arna H Arnardottir1, Sabine M J Straus2,3

  • 1Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

British Journal of Clinical Pharmacology
|December 4, 2014
PubMed
Summary
This summary is machine-generated.

Regulators, doctors, and patients generally agree on the importance of major drug benefits and risks for type 2 diabetes oral antidiabetic drugs. However, subtle differences emerge in valuing minor or short-term treatment effects.

Keywords:
benefit-risk assessmentdrug preferenceoral antidiabetes drugsurvey

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.5K

Related Experiment Videos

Last Updated: Apr 20, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.3K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.5K

Area of Science:

  • Pharmacology
  • Health Economics
  • Patient-Reported Outcomes

Background:

  • Type 2 diabetes management involves oral antidiabetic drugs with diverse effects.
  • Understanding stakeholder values (regulators, doctors, patients) is crucial for drug evaluation.
  • Previous research has not fully compared these specific value perceptions.

Purpose of the Study:

  • To compare the valuation of different drug effects of oral antidiabetic drugs among regulators, doctors, and patients.
  • To identify potential discrepancies in prioritizing drug attributes.

Main Methods:

  • A discrete choice survey was administered to regulators, doctors, and patients with type 2 diabetes in The Netherlands.
  • Eighteen choice sets compared hypothetical oral antidiabetic drugs based on varying effects (glycated haemoglobin, cardiovascular risk, bodyweight, gastrointestinal complaints, hypoglycemia, bladder cancer risk).
  • Multinomial conditional logit analyses were used to assess preferences.

Main Results:

  • Cardiovascular risk reduction was positively valued by regulators, while persistent gastrointestinal problems and cardiovascular risk increase were negatively valued.
  • Doctors and patients generally mirrored regulators' valuation of major benefits and risks.
  • Differences were observed in valuing less frequent hypoglycemic episodes, with regulators valuing them less than patients.

Conclusions:

  • Regulators and clinicians largely align with patient preferences on major drug benefits and risks for type 2 diabetes.
  • Divergences in valuing minor or short-term drug effects may exist between regulators and patients.
  • This highlights the importance of considering diverse stakeholder perspectives in drug development and regulation.